

1. (Amended) A pharmaceutical composition for vaccination against cancer comprising at least one antibody directed against the cellular membrane antigen Ep-CAM.

3. (Amended) The pharmaceutical composition of claim 1, wherein said antibody is a monoclonal antibody.

4. (Amended) The pharmaceutical composition of claim 3, wherein said antibody is a murine monoclonal antibody, wherein the variable region of the heavy chain is the amino acid sequence as shown in SEQ ID NO:1 and wherein the variable region of the light chain is the amino acid sequence as shown in SEQ ID NO:2.

5. (Amended) The pharmaceutical composition of any one of claims 1-3, wherein said antibody has the same fine specificity of binding as the antibody defined in claim 4.

6. (Amended) The pharmaceutical composition of claim 1, wherein said antibodies are directed against different epitopes of the membrane antigen.

7. (Amended) The pharmaceutical composition of claim 1, further comprising at least one vaccine adjuvant.

8. (Amended) A method of vaccination against cancer comprising administering to a patient in need thereof the pharmaceutical composition of claim 1 at a dosage in the range of 0.01 to 4 mg antibody.